RIO kinase (RIOK) are a class of highly conserved atypical serine/threonine kinases, mainly including RIOK1, RIOK2, and RIOK3. RIOK possess both kinase and ATPase characteristics, and their core functions primarily involve the maturation of the pre-40S ribosomal small subunit, 18S rRNA processing, and ribosome biogenesis, thereby maintaining protein translation capacity and cell proliferation. RIOK are not only ribosome assembly factors but also crucial nodes connecting the translation system and oncogenic signaling. RIOK1/2 can enhance ribosome production, protein translation, and AKT/mTOR signaling output, promoting cell proliferation, EMT, and tumor progression; RIOK3 participates in the TBK1-IRF3-IFN and NF-κB pathways, regulating innate immune and inflammatory responses. Due to the high dependence of cancer cells on ribosome production and translation capacity, RIOK have become an emerging anticancer target.
CQ3196 是一种口服 RIOK2 抑制剂,Kd 值为 14 nM,能有效抑制 RIOK2 的 ATPase 活性(IC50 值为 72 nM),抑制胃癌细胞系的细胞增殖和集落形成,诱导 HGC-27 和 AGS 细胞凋亡 (apoptosis),抑制 RIOK2 的下游信号通路,降低 mTOR 和 AKT 磷酸化,调节核糖体功能和蛋白质合成,并抑制肿瘤生长,可用于胃癌的体内外研究。
ERGi-USU-6 mesylate(Compound 7b)是一种 ERG 和 RIOK2 抑制剂,在 VCaP 细胞中的 IC50 值分别为 0.17 μM 和 0.13 μM,并对 ERG 阳性前列腺癌表现出抗癌活性。
RIOK2-IN-1 (com 4) 是一种有效的选择性 RIOK2 抑制剂(Kd=150 nM),但细胞活性较低(IC50=14,600 nM),而 RIOK2 是一种与多种人类癌症有关的非典型激酶,参与核糖体成熟和细胞周期进展;以 RIOK2-IN-1 为先导化合物改进得到的小分子抑制剂 CQ211 (MS-R90191) 具有良好的体内外活性,可抑制 MKN-1 和 HT-29 癌细胞的增殖,并在小鼠异种移植 MKN-1 模型中抑制肿瘤进展。
RIOK2-IN-2 (8) 是一种 RIOK2 抑制剂,在 MKN-1 和 MOLT4 中的 IC50 值分别为 3.02 μM 和 5.34 μM。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号